Skip to content

Study to Evaluate Tetanizing Burst Therapy in Patients Undergoing ICD Replacement

Evaluation of the Ongoing Safety and Preliminary Efficacy of the Tetanizing Burst Therapy (TBT) System in Subjects Undergoing ICD Replacement Due to End-of-battery Life

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03628911
Enrollment
50
Registered
2018-08-14
Start date
2018-01-01
Completion date
2020-12-01
Last updated
2019-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Electrophysiology

Brief summary

This study evaluates whether the addition of tetanizing burst therapy reduces the pain associated with ICD shocks

Detailed description

The implantable cardioverter defibrillator is a device designed to rescue patients from life-threatening arrhythmias by delivering a defibrillation shock to allow restoration of cardiac rhythm. These defibrillation shocks are extremely painful, owing to sudden rapid contraction of thoracic and abdominal skeletal muscle, which, in addition to the heart, are stimulated by the defibrillation shock. Tetanizing Burst Therapy is a novel electrical waveform which tetanizes skeletal muscle with a brief burst of stimulation prior to the ICD shock, thereby reducing muscular contraction due to the shock. This study is designed for those patients who are already undergoing ICD replacement.

Interventions

DEVICETetanizing Burst Therapy

Tetanizing Burst Therapy tetanizes skeletal muscle with a brief burst of stimulation prior to ICD shock, thereby reducing muscular contraction due to the shock

Sponsors

EP Sciences
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Male or Female age 18-80 years, inclusive * Ability to understand and provide written informed consent * Normal sinus rhythm * Standard transvenous left-sided ICD referred for device replacement due to end of battery life

Exclusion criteria

* Heart rate \<40 or \>90 bpm * Atrial fibrillation or pacemaker dependent * NYHA Class III/IV symptoms of HF * MI within 90 days of enrollment * Severe cardiac ischemia manifested by chest pain at rest or with minimal exercise * History stroke or TIAs * History of prior ICD pocket infection * ICD lead resistance that is too high or too low in the opinion of the investigator * Female who is pregnant or breastfeeding * Prior heart transplant * Serum electrolytes out of normal range at participating institution

Design outcomes

Primary

MeasureTime frameDescription
Less pain after TBT impulse with ICD shock compared to ICD shock alone5 minutesEach subject will receive 2 therapies in random order delivered 5 minutes apart: * Tetanizing Burst Therapy + shock; and * Pure shock alone. Using the Numeric Pain Rating Scale (NRS) after each shock, the subject will be asked to provide a verbal score between 1 and 10, where 1 is no pain and 10 is the worst pain imaginable.

Secondary

MeasureTime frameDescription
The efficacy of tetanizing burst therapy in subjects undergoing ICD replacement as assessed by NRS verbal score5 minutesAfter each shock, a blinded assessor will ask the subject to provide an NRS verbal score between 1 and 10, where 1 is no pain and 10 is the worst pain imaginable. The percent change in the NRS score will be calculated for each subject along with the change in skeletal muscle force waveform
The safety of tetanizing burst therapy in subjects undergoing ICD replacement as assessed by adverse events7 daysIncidence rates of all adverse events will be calculated and compared to event rates in the literature. They will also be analyzed by severity and relationship to the device and/or study procedures.
The device performance of tetanizing burst therapy in subjects undergoing ICD replacement as assessed degree of muscle contraction (Rate of Force Development)5 minutesThe force of contraction is recorded at the patient's left elbow with a myometer

Countries

United States

Contacts

Primary ContactJane Wilson
janew@databean.com8457218210

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026